Wall Street Experts
ver. ZuMIgo(08/25)
Tarsus Pharmaceuticals, Inc.
Rachunek Zysków i Strat
Przychody TTM (mln): 130
EBIT TTM (mln): -128
index |
0 |
1 |
2 |
3 |
4 |
5 |
6 |
Rok finansowy |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Przychód (mln) |
0 |
0 |
0 |
57 |
26 |
17 |
183 |
Przychód Δ r/r |
0.0% |
0.0% |
0.0% |
inf% |
-54.7% |
-32.4% |
948.6% |
Marża brutto |
0.0% |
-inf% |
-inf% |
96.4% |
96.3% |
90.9% |
93.0% |
EBIT (mln) |
-1 |
-4 |
-27 |
-12 |
-63 |
-143 |
-121 |
EBIT Δ r/r |
0.0% |
218.4% |
528.2% |
-55.0% |
415.9% |
128.3% |
-15.8% |
EBIT (%) |
0.0% |
0.0% |
0.0% |
-21.3% |
-242.9% |
-820.5% |
-65.9% |
Koszty finansowe (mln) |
0 |
0 |
0 |
0 |
2 |
3 |
7 |
EBITDA (mln) |
-1 |
-4 |
-27 |
-11 |
-59 |
-142 |
-107 |
EBITDA(%) |
0.0% |
0.0% |
0.0% |
-18.6% |
-229.0% |
-815.5% |
-58.4% |
Podatek (mln) |
0 |
0 |
0 |
0 |
-0 |
0 |
0 |
Zysk Netto (mln) |
-1 |
-5 |
-27 |
-14 |
-62 |
-136 |
-116 |
Zysk netto Δ r/r |
0.0% |
254.1% |
474.1% |
-48.4% |
349.1% |
118.9% |
-15.0% |
Zysk netto (%) |
0.0% |
0.0% |
0.0% |
-24.2% |
-240.5% |
-778.9% |
-63.2% |
EPS |
-0.31 |
-0.24 |
-1.32 |
-0.67 |
-2.52 |
-4.62 |
-3.07 |
EPS (rozwodnione) |
-0.31 |
-0.24 |
-1.32 |
-0.67 |
-2.52 |
-4.62 |
-3.07 |
Ilośc akcji (mln) |
4 |
20 |
20 |
21 |
25 |
29 |
38 |
Ważona ilośc akcji (mln) |
4 |
20 |
20 |
21 |
25 |
29 |
38 |
Waluta |
USD |
USD |
USD |
USD |
USD |
USD |
USD |